ALZN
Alzamend Neuro Inc
NASDAQ: ALZN · HEALTHCARE · BIOTECHNOLOGY
$1.14
+7.55% today
Updated 2026-04-30
Market cap
$4.22M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.67
Dividend yield
—
52W range
$1 – $6
Volume
0.1M
Alzamend Neuro Inc (ALZN) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-66.3%
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+66.1%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-3.4%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-4.0%
2025-12-09
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-01-31 | $-0.58 | -9.4% | $2.15 | $2.09 | -2.8% |
| 2025-12-09 | $-0.30 | +50.8% | $2.25 | $2.16 | -4.0% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-01-31 | $-0.53 | $-0.58 | -9.4% | — | — |
| 2025-10-31 | $-0.61 | $-0.30 | +50.8% | — | — |
| 2025-07-31 | $-0.62 | $-1.28 | -106.5% | — | — |
| 2025-04-30 | $-2.70 | $-9.48 | -251.1% | — | — |
| 2025-01-31 | $-3.19 | $-1.71 | +46.4% | — | — |
| 2024-10-31 | $-3.42 | $-3.60 | -5.3% | — | — |
| 2024-07-31 | $-2.38 | $-1.25 | +47.5% | — | — |
| 2024-04-30 | $-2.75 | $-13.35 | -385.5% | $76110.00 | — |
| 2024-01-31 | $-0.32 | $-0.38 | -18.8% | — | — |
| 2023-10-31 | $-0.67 | $-0.44 | +34.3% | — | — |
| 2023-07-31 | $-0.04 | $-0.04 | +0.0% | — | — |
| 2023-04-30 | $-0.04 | $-0.03 | +25.0% | — | — |
Frequently asked questions
Has Alzamend Neuro Inc beaten earnings estimates?
Alzamend Neuro Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -66.3% over the last 4 quarters.
How does ALZN stock react to earnings?
ALZN stock has moved an average of -3.4% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.